Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma.
[IMPORTANCE] International guidelines lack consistency in their recommendations regarding routine imaging in the follow-up after pancreatic resection for pancreatic ductal adenocarcinoma (PDAC).
- p-value P = .01
- 95% CI 19-29
- 연구 설계 cross-sectional
APA
Andel PCM, van Goor IWJM, et al. (2025). Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma.. JAMA surgery, 160(1), 74-84. https://doi.org/10.1001/jamasurg.2024.5024
MLA
Andel PCM, et al.. "Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma.." JAMA surgery, vol. 160, no. 1, 2025, pp. 74-84.
PMID
39504033
Abstract
[IMPORTANCE] International guidelines lack consistency in their recommendations regarding routine imaging in the follow-up after pancreatic resection for pancreatic ductal adenocarcinoma (PDAC). Consequently, follow-up strategies differ between centers worldwide.
[OBJECTIVE] To compare clinical outcomes, including recurrence-focused treatment and survival, in patients with PDAC recurrence who received symptomatic follow-up or routine imaging after pancreatic resection in international centers affiliated with the European-African Hepato-Pancreato-Biliary Association (E-AHPBA).
[DESIGN, SETTING, AND PARTICIPANTS] This was a prospective, international, cross-sectional study. Patients from a total of 33 E-AHPBA centers from 13 countries were included between 2020 and 2021. According to the predefined study protocol, patients who underwent PDAC resection and were diagnosed with disease recurrence were prospectively included. Patients were stratified according to postoperative follow-up strategy: symptomatic follow-up (ie, without routine imaging) or routine imaging.
[EXPOSURES] Symptomatic follow-up or routine imaging in patients who underwent PDAC resection.
[MAIN OUTCOMES AND MEASURES] Overall survival (OS) was estimated with Kaplan-Meier curves and compared using the log-rank test. To adjust for potential confounders, multivariable logistic regression was used to evaluate the association between follow-up strategy and recurrence-focused treatment. Multivariable Cox proportional hazard analysis was used to study the independent association between follow-up strategy and OS.
[RESULTS] Overall, 333 patients (mean [SD] age, 65 [11] years; 184 male [55%]) with PDAC recurrence were included. Median (IQR) follow-up at time of analysis 2 years after inclusion of the last patient was 40 (30-58) months. Of the total cohort, 98 patients (29%) received symptomatic follow-up, and 235 patients (71%) received routine imaging. OS was 23 months (95% CI, 19-29 months) vs 28 months (95% CI, 24-30 months) in the groups who received symptomatic follow-up vs routine imaging, respectively (P = .01). Routine imaging was associated with receiving recurrence-focused treatment (adjusted odds ratio, 2.57; 95% CI, 1.22-5.41; P = .01) and prolonged OS (adjusted hazard ratio, 0.75; 95% CI, 0.56-.99; P = .04).
[CONCLUSION AND RELEVANCE] In this international, prospective, cross-sectional study, routine follow-up imaging after pancreatic resection for PDAC was independently associated with receiving recurrence-focused treatment and prolonged OS.
[OBJECTIVE] To compare clinical outcomes, including recurrence-focused treatment and survival, in patients with PDAC recurrence who received symptomatic follow-up or routine imaging after pancreatic resection in international centers affiliated with the European-African Hepato-Pancreato-Biliary Association (E-AHPBA).
[DESIGN, SETTING, AND PARTICIPANTS] This was a prospective, international, cross-sectional study. Patients from a total of 33 E-AHPBA centers from 13 countries were included between 2020 and 2021. According to the predefined study protocol, patients who underwent PDAC resection and were diagnosed with disease recurrence were prospectively included. Patients were stratified according to postoperative follow-up strategy: symptomatic follow-up (ie, without routine imaging) or routine imaging.
[EXPOSURES] Symptomatic follow-up or routine imaging in patients who underwent PDAC resection.
[MAIN OUTCOMES AND MEASURES] Overall survival (OS) was estimated with Kaplan-Meier curves and compared using the log-rank test. To adjust for potential confounders, multivariable logistic regression was used to evaluate the association between follow-up strategy and recurrence-focused treatment. Multivariable Cox proportional hazard analysis was used to study the independent association between follow-up strategy and OS.
[RESULTS] Overall, 333 patients (mean [SD] age, 65 [11] years; 184 male [55%]) with PDAC recurrence were included. Median (IQR) follow-up at time of analysis 2 years after inclusion of the last patient was 40 (30-58) months. Of the total cohort, 98 patients (29%) received symptomatic follow-up, and 235 patients (71%) received routine imaging. OS was 23 months (95% CI, 19-29 months) vs 28 months (95% CI, 24-30 months) in the groups who received symptomatic follow-up vs routine imaging, respectively (P = .01). Routine imaging was associated with receiving recurrence-focused treatment (adjusted odds ratio, 2.57; 95% CI, 1.22-5.41; P = .01) and prolonged OS (adjusted hazard ratio, 0.75; 95% CI, 0.56-.99; P = .04).
[CONCLUSION AND RELEVANCE] In this international, prospective, cross-sectional study, routine follow-up imaging after pancreatic resection for PDAC was independently associated with receiving recurrence-focused treatment and prolonged OS.
MeSH Terms
Humans; Pancreatic Neoplasms; Male; Female; Aged; Middle Aged; Prospective Studies; Cross-Sectional Studies; Neoplasm Recurrence, Local; Pancreatectomy; Carcinoma, Pancreatic Ductal; Survival Rate; Follow-Up Studies
같은 제1저자의 인용 많은 논문 (4)
- ASO Author Reflections: The Impact of Perioperative Treatment on Recurrence Treatment for Pancreatic Cancer.
- Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma.
- Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis.
- ASO Author Reflections: The Impact of Adjuvant Therapy in the Era of Neoadjuvant Strategies for Pancreatic Cancer.